Level C· Early human research exploring benefitsCase Report / SeriesEurope PMC

Application of platelet-rich plasma in treating refractory wounds following hemorrhoid surgery: a case report

Yang Y., Meng Z., Gao K., Zhang C., Gao M., Wang H.

Case Report / Series on Autoimmune Research, published in Am J Transl Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Am J Transl Res (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41113044
PMCID
PMC12531563
DOI
10.62347/zwnq5726

Abstract (original English)

This case report presents the successful application of autologous Platelet-rich Plasma (PRP) in treating a 53-year-old male patient with a nonhealing perianal wound that persisted for 71 days following surgery for mixed hemorrhoid and anal fistula, despite conventional therapies, including topical traditional Chinese medicine, antibiotics, and wound care. A series of three PRP treatments, administered on October 25, October 27, and November 1, 2023, accelerated healing, resulting in complete closure of the 1.6 cm wound within 14 days. This was accompanied by reduced pain and no recurrence at follow-up, demonstrating PRP's effectiveness in promoting tissue regeneration, controlling infection, and relieving pain in a refractory post-surgical wound.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research